Skip to main content
OpenTrials
Completed

NCT Number: NCT05079607

Human Skin Safety Testing of a Mitopure Topical Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers

The objective of this study is to investigate the irritation and sensitization potential of multiple topically applied test articles (containing different concentrations of Mitopure), in a shared panel of healthy volunteers by means of repeated cutaneous patch applications under occlusion based on the modified Draize method

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PCR Corp, 667A Stockport Road

Manchester, M12 4QE, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males or females,18 years of age or older.
  • Completed written informed consent.
  • Female subject agrees to use an acceptable method of birth control (e.g. abstinence, condoms, hormonal birth control, IUD, tubal ligation, hysterectomy, bilateral oophorectomy, hysterectomy, post-menopausal for at least one year or male partner vasectomy).

Exclusion criteria

  • Pregnancy or lactation.
  • A current skin disease of any type apart from mild facial acne (e.g. eczema, psoriasis) or has tattoos or excessive hair at the patch sites that would interfere with patching/skin evaluations.
  • Heavy alcohol consumption (i.e. more than 21 units per week or 8 units a day for men, more than 14 units per week or 4 units a day for women).
  • Current use or history of repeated use of street drugs.
  • A febrile illness lasting more than 24 hours in the six days prior to first patch application.
  • Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease.
  • Currently taking asthma medication or antihistamines for hay fever.
  • A history of multiple drug hypersensitivity.
  • Concurrent medication likely to affect the response to the test articles or confuse the results of the study (e.g. Anti-allergy, glucocorticoid, aspirin, non- steroidal anti-inflammatory, asthma or hay fever medication).
  • Known sensitivity to the test articles or their constituents including patch materials (for example tape/plaster adhesive).
  • Current treatment by a physician for allergy unless physician consulted by Investigator and participation approved.
  • Participation in a repeat insult patch test (RIPT) or follow-up work within the last month.
  • Sensitisation or questionable sensitisation in a RIPT.
  • Recent immunisation (less than 10 days prior to test patch application).
  • A medical history indicating atopy.

Treatment and study plan

Mitopure Topical Formula 1

Other

topical skin cream containing the low dose mitophagy activator Mitopure

Mitopure Topical Formula 2

Other

topical skin cream containing the high dose mitophagy activator Mitopure

Primary outcomes

  1. Skin safety as assessed by the number of adverse events of skin irritation and sensitization during human repeat insult patch testing (HRIPT)

    Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

Amazentis SA

Industry

Collaborators

  • Princeton Research Corporation

Registry information

Official study title

A Modified Draize Repeat Insult Patch Test in a Shared Panel of 50/100 Healthy Volunteers, to Investigate the Irritation and Sensitization Potential of Test Articles Following Repeated Cutaneous Patch Applications

Acronym: GLOW-Safety

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Oct 15, 2021
Registry last updated
Nov 23, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.